Company Analysis
Sign in

Caribou Biosciences, Inc. (CRBU)

Nasdaq: CRBU · Biological Products, (No Diagnostic Substances) · Berkeley, CA · filing with the SEC since 2014
Full chart Alerts Compare
Grade4.8
◀ Past 5.8● Present 4.7▶ Future 4.2
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

58 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Caribou Biosciences, Inc.’s names, not what it holds today.

Patents granted
58
58 utility, 1976 to Dec 31, 2025
Granted in 2025
4
Against 2 in 2024 and 1 in 2023
Applications published
91
14 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Biotechnology22
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Caribou Biosciences, Inc. its own name
US, as the owner printed on each patent
58 granted
38 published
Caribou Biosciences, Inc. its own name
named as the applicant on its applications, in US
0 granted
53 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 9, 202512,492,264Anti-ROR1 antibody and ROR1-targeting engineered cellsBiotechnologyCaribou Biosciences, Inc.
Oct 7, 202512,435,152Humanized BCMA antibody and BCMA-CAR-T cellsBiotechnologyCaribou Biosciences, Inc.
Sep 16, 202512,416,045Method of capturing CRISPR endonuclease cleavage productsBiotechnologyCaribou Biosciences, Inc.
Feb 18, 202512,227,776Engineered cascade components and cascade complexesBiotechnologyCaribou Biosciences, Inc.
Mar 26, 202411,939,604Modified cascade ribonucleoproteins and uses thereofBiotechnologyCaribou Biosciences, Inc.
Mar 19, 202411,932,703Anti-ROR1 antibody and ROR1-targeting engineered cellsBiotechnologyCaribou Biosciences, Inc.
Jan 17, 202311,555,181Engineered cascade components and cascade complexesBiotechnologyCaribou Biosciences, Inc.
Nov 22, 202211,505,808Engineered nucleic acid-targeting nucleic acidsBiotechnologyCaribou Biosciences, Inc.
Oct 18, 202211,472,884Humanized BCMA antibody and BCMA-CAR-T cellsBiotechnologyCaribou Biosciences, Inc.
Oct 4, 202211,459,588Methods of use of CRISPR CPF1 hybrid DNA/RNA polynucleotidesBiotechnologyCaribou Biosciences, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 11, 20252025/0376700CRISPR HYBRID DNA/RNA POLYNUCLEOTIDES AND METHODS OF USEBiotechnologyCaribou Biosciences, Inc.
Nov 13, 20252025/0345424TREATMENT OF AUTOIMMUNE DISEASES WITH ENGINEERED IMMUNE CELLSBiotechnologyCaribou Biosciences, Inc.
Nov 6, 20252025/0339465ANTI-ROR1 ANTIBODY AND ROR1-TARGETING ENGINEERED CELLSBiotechnologyCaribou Biosciences, Inc.
Oct 30, 20252025/0332196ANTI-CLL-1 CHIMERIC ANTIGEN RECEPTORS, ENGINEERED CELLS AND RELATED METHODSMedical technologyCaribou Biosciences, Inc.
Oct 23, 20252025/0327048MODIFIED CASCADE RIBONUCLEOPROTEINS AND USES THEREOFBiotechnologyCaribou Biosciences, Inc.
Oct 23, 20252025/0325698THERAPEUTIC APPLICATIONS OF CRISPR TYPE V SYSTEMSBiotechnologyCaribou Biosciences, Inc.
Oct 16, 20252025/0320490COMPOSITIONS AND METHODS OF NUCLEIC ACID-TARGETING NUCLEIC ACIDSBiotechnologyCaribou Biosciences, Inc.
Jul 17, 20252025/0230424MODIFIED CASCADE RIBONUCLEOPROTEINS AND USES THEREOFBiotechnologyCaribou Biosciences, Inc.
Jul 10, 20252025/0223578MODIFIED CASCADE RIBONUCLEOPROTEINS AND USES THEREOFBiotechnologyCaribou Biosciences, Inc.
May 22, 20252025/0163171HUMANIZED BCMA ANTIBODY AND BCMA-CAR-T CELLSBiotechnologyCaribou Biosciences, Inc.
What it applied for, 2024 to 2025: Biotechnology 18 · Medical technology 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton CRBU · research, not advice